Suitable for use to measure free Tocilizumab in patient samples.
Recommended antibody pair for pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB253 - CABT-ZB254; CABT-ZB253 - CABT-ZB255
Recommended Working Concentration: 0.01-0.1 μg/ml
Summary
Specifications
Antibody Isotype
IgG2b
Clone
25C21
Immunogen
Tocilizumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB253 - CABT-ZB254; CABT-ZB253 - CABT-ZB255 Recommended Working Concentration: 0.01-0.1 μg/ml
General Notes
We recommend the following antibody pair to develop a pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB253 - CABT-ZB254; CABT-ZB253 - CABT-ZB255 CABT-ZB253 is recommended for use as a capture antibody when paired with CABT-ZB254 or CABT-ZB255 as a detection antibody. Tocilizumab also known as atlizumab, is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration. It has a high affinity to IL-6R and blocks the IL-6 signaling by preventing the formation of the IL-6/IL-6R complex. Tocilizumab is used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children.
Target
Alternative Names
Mouse monoclonal antibody to Actemra; Tocilizumab; atlizumab
Citations
Publication ()
Have you cited CABT-ZB253 in a publication? Let us know and earn a reward for your research.
My Review for Mouse Anti-Tocilizumab monoclonal antibody, clone 25C21
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
